Metropolis Healthcare · NSE: METROPOLIS · BSE: 542650
Q2 FY25 results · Jul–Sep 2024
Metropolis Healthcare reported revenue from operations of ₹349.79 crore (up 13.4% from Q2 FY24) and net profit of ₹46.70 crore (up 31.0% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 349.79 | 308.50 | +13.4% | 313.36 | +11.6% |
| Other income | 3.13 | 1.22 | +156.7% | 2.46 | +27.3% |
| Total income | 352.92 | 309.72 | +13.9% | 315.81 | +11.7% |
| Profit before tax | 61.40 | 48.11 | +27.6% | 51.08 | +20.2% |
| Net profit for the period | 46.70 | 35.66 | +31.0% | 38.11 | +22.5% |
| Attributable to shareholders of the company | 46.52 | 35.45 | +31.2% | 37.95 | +22.6% |
| EPS, basic (₹) | 9.08 | 6.92 | +31.2% | 7.41 | +22.5% |
| Net margin (%) | 13.4 | 11.6 | 12.2 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 321.57 | 285.46 | +12.7% | 286.14 | +12.4% |
| Other income | 3.59 | 2.01 | +78.9% | 2.83 | +27.1% |
| Total income | 325.16 | 287.46 | +13.1% | 288.96 | +12.5% |
| Profit before tax | 54.87 | 42.49 | +29.1% | 41.72 | +31.5% |
| Net profit for the period | 42.26 | 31.28 | +35.1% | 31.28 | +35.1% |
| EPS, basic (₹) | 8.24 | 6.11 | +34.9% | 6.11 | +34.9% |
| Net margin (%) | 13.1 | 11.0 | 10.9 |
Consolidated
- Filed with BSE
- 08 Nov 2024, 20:58 IST
- Board meeting
- 08 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 08 Nov 2024, 20:58 IST
- Board meeting
- 08 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE